Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,220.66 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Jul 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Eli Lilly & Co. (NYSE:LLY) Stands Out With High Growth Momentum and a Breakout Setup ↗

July 17, 2026

Via Chartmill

Why AtaiBeckley Stock Soared Today ↗

July 16, 2026

The psychedelic drugmaker is being acquired.

Via The Motley Fool

Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion ↗

July 16, 2026

Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.

Via The Motley Fool

Topics Government Stocks

This GLP-1 Stock Could Double by 2030. Here's Why ↗

July 16, 2026

Investors need to ask tough questions before initiating a position in this biotech company.

Via The Motley Fool

Eli Lilly & Co. (NYSE:LLY) Passes Navellier’s High-Growth Screen on Strong Earnings and Sales Momentum ↗

July 14, 2026

Via Chartmill

Why Is GH Research Stock Trading Higher on Thursday? ↗

July 16, 2026

GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.

Via Benzinga

AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal ↗

July 16, 2026

Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)

July 16, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026? ↗

July 16, 2026

One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.

Via The Motley Fool

Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETF ↗

July 16, 2026

IXJ's market-cap weighting and international exposure delivered stronger five-year returns and lower volatility, while offering double the dividend yield.

Via The Motley Fool

Topics ETFs

Eli Lilly Trips Into Red-Hot Psychedelics Space With A Big Takeover ↗

July 16, 2026

Eli Lilly tripped into the psychedelics space Thursday with the up to $3.8 billion acquisition of AtaiBeckley.

Via Investor's Business Daily

Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH? ↗

July 16, 2026

IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles.

Via The Motley Fool

Topics ETFs

Meta, Vistra, T. Rowe Price and a Health Care Stock on CNBC’s ‘Final Trades’ ↗

July 16, 2026

Bill Baruch chose Eli Lilly as his final trade, supported by Citigroup's analyst. Other experts recommended Vistra, Meta Platforms, and T. Rowe Price.

Via Benzinga

The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo? ↗

July 16, 2026

FDA advisors will debate the merits of seven peptides next week. The discussion could have an impact on Lilly and Novo.

Via Investor's Business Daily

AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Reported Eli Lilly Acquisition Talks (CORRECTED) ↗

July 16, 2026

AtaiBeckley shares jumped 64.70% after hours following reports that Eli Lilly is in talks to acquire the psychedelic drugmaker at a premium.

Via Benzinga

As Medicare’s New GLP-1 Coverage Begins, Ozari Health Publishes 2026 Guide Comparing Every Way to Get Semaglutide and Tirzepatide – From $50 Copays to $86 Cash-Pay Options

July 15, 2026

Via AB Newswire

If You Invested $1000 In Eli Lilly Stock 5 Years Ago, You Would Have This Much Today ↗

July 15, 2026

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.47% on an annualized basis producing an average annual return of 37.22%. Currently, Eli Lilly has a market capitalization of...

Via Benzinga

Why Vivosim Labs Shares Are Rocketing on Wednesday? ↗

July 15, 2026

VivoSim Labs shares climbed after receiving a $5 million Eli Lilly milestone payment and forecasting more than 500% revenue growth in FY2027.

Via Benzinga

3 Vanguard ETFs Poised to Outperform as the Market Shifts Beyond Big Tech ↗

July 15, 2026

With investors finally embracing market segments beyond technology, these three Vanguard ETFs are winning.

Via The Motley Fool

Topics ETFs

2 Beaten-Down GLP-1 Stocks to Buy on the Dip ↗

July 15, 2026

Don't wait until clinical milestones send their share prices soaring.

Via The Motley Fool

Can Biogen Score Another Win In Alzheimer's Disease? ↗

July 14, 2026

Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over 18 months.

Via Investor's Business Daily

Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market? ↗

July 14, 2026

Eyes are on the rollout of Lilly's new weight loss pill.

Via The Motley Fool

Cathie Wood Bought $54 Million Worth Of SpaceX Stock Last Week ↗

July 13, 2026

Cathie Wood's ARK Invest was extremely active last week, adding SpaceX and Meta, while selling AMD and Robinhood stock.

Via Investor's Business Daily

Topics ETFs

Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades ↗

July 13, 2026

Eli Lilly shares are in the spotlight Monday as the company presents new Kisunla data at the AAIC in London.

Via Benzinga

Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors ↗

July 13, 2026

Two drugs now generate almost two-thirds of the pharmaceutical giant's revenue.

Via The Motley Fool

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? ↗

July 11, 2026

IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.

Via The Motley Fool

Topics ETFs

Which is the Better Choice for Healthcare Investors? IYH or BBH? ↗

July 11, 2026

BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield.

Via The Motley Fool

Topics ETFs

Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It? ↗

July 11, 2026

One small investment offers big benefits for Nvidia.

Via The Motley Fool

Topics Artificial Intelligence

3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026 ↗

July 11, 2026

This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.

Via The Motley Fool

Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗

July 11, 2026

There are good reasons to invest in Lilly and to hold off.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.